A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention

Journal of Endovascular Therapy

Volumn 22, Issue 2, 2015, Pages 261-268

  Tangelder, Marco J D ^a   Nwachuku, Chuke E ^b   Jaff, Michael ^c   Baumgartner, Iris ^d   Duggal, Anil ^b   Adams, George ^e   Ansel, Gary ^f   Grosso, Michael ^b   Mercuri, Michele ^b   Shi, Minggao ^b   Minar, Erich ^g   Moll, Frans L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b DAIICHI SANKYO INC   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BERN UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^f RIVERSIDE METHODIST HOSPITAL   (United States)

^g UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angioplasty; Antiplatelet therapy; Antithrombotic therapy; Aspirin; Bleeding; Clopidogrel; Edoxaban; Endovascular therapy; Factor Xa inhibitor; Femoropopliteal segment; Peripheral artery disease; Randomized controlled trial; Restenosis; Stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EDOXABAN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOLYTIC AGENT; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; TICLOPIDINE;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; HUMAN; MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; TREATMENT DURATION; TREATMENT OUTCOME; ULTRASOUND; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; ANGIOPLASTY; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DEVICES; EUROPE; FEMALE; FEMORAL ARTERY; ISRAEL; MALE; METHODOLOGY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STENT; TIME FACTOR; UNITED STATES;

AGED; ANGIOPLASTY; ASPIRIN; DRUG THERAPY, COMBINATION; EUROPE; FACTOR XA INHIBITORS; FEMALE; FEMORAL ARTERY; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; ISRAEL; MALE; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; POPLITEAL ARTERY; PYRIDINES; RESEARCH DESIGN; RISK FACTORS; STENTS; THIAZOLES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84940030832     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1177/1526602815574687     Document Type: Article

References (29)

1. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26:517-538.
2. Dormandy J, Mahir M, Ascady G, et al. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino). 1989;30:50-57.
3. Hertzer NR. The natural history of peripheral vascular disease. Implications for its management. Circulation. 1991;83:112-119.
4. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(suppl 1):S1-S75.
5. Ihnat DM, Mills JL Sr. Current assessment of endovascular therapy for infrainguinal arterial occlusive disease in patients with diabetes. J Vasc Surg. 2010;52(3 suppl):92S-95S.
6. Heiss HW, Just H, Middleton D, et al. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology. 1990;41:263-269.
7. Study Group on Pharmacological Treatment after PTA. Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial. Eur J Vasc Surg. 1994;8:83-88.
8. Dörffler-Melly J, Koopman MM, Prins MH, et al. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2005;(1):CD002071.
9. Milani RV. Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? Catheter Cardiovasc Interv. 2009;74(suppl 1):S7-S11.
10. Tepe G, Bantleon R, Brechtel K, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy-the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol. 2012;22:1998-2006.
11. Strobl FF, Brechtel K, Schmehl J, et al. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease. J Endovasc Ther. 2013;20:699-706.
12. Schneider E, Mahler F, Do DD, et al. Zur Rezidivprophylaxe nach perkutaner transluminaler angioplastie (PTA): Antikoagulation versus Ticlopidin. Vasa. 1987;16(suppl 20):355-356.
13. Pilger E, Lammer J, Bertuch H, et al. Nd:Yag laser with sapphire tip combined with balloon angioplasty in peripheral arterial occlusions: long-term results. Circulation. 1991;83:141-147.
14. Do DD, Mahler F. Low-dose aspirin combined with dipyridamole versus anticoagulants after femoropopliteal percutaneous transluminal angioplasty. Radiology. 1994;193:567-571.
15. Koppensteiner R, Spring S, Mann-Vesti BR, et al. Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial. J Vasc Surg. 2006;44:1247-1253.
16. Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e669S-e690S.
17. European Stroke Organisation. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2851-2906.
18. Schwartz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol. 1998;81:14E-17E.
19. Ward MR, Tsao PS, Agrotis A, et al. Low blood flow after angioplasty augments mechanisms of restenosis: inward vessel remodeling, cell migration, and activity of genes regulating migration. Arterioscler Thromb Vasc Biol. 2001;21;208-213.
20. Kearney M, Pieczek A, Haley L, et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation. 1997;95:1998-2002.
21. Matsushima N, Lee F, Sato T, et al. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharm Drug Dev. 2013;2:358-366.
22. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50:743-753.
23. Salazar DE, Mendell J, Kastrissios H, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012;107:925-936.
24. Yamashita T, Koretsune Y, Yasaka M, et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J. 2012;76:1840-1847.
25. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406-1415.
26. Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104.
27. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-694.
28. Büller HR, Cohen AT, Davidson B, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007;357:1094-1104.
29. Chin CT, Roe MT, Fox KA, et al.; TRILOGY ACS Steering Committee. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J. 2010;160:16-22.e1.